Expression of NPY4R in glioma - The Human Protein Atlas

We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.

SUMMARY

TISSUE

BRAIN

SINGLE CELL

SUBCELL

CANCER

BLOOD

CELL LINE

STRUCTURE

INTERACTION

NPY4R

GLIOBLASTOMA MULTIFORME (TCGA) - Interactive survival scatter plotⁱ

The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.

The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".

Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.

Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.

& Survival analysisⁱ

NPY4R is not prognostic in Glioblastoma Multiforme (TCGA)

Stage:

Survival analysis

Current cut offⁱ :

Best expression cut offⁱ : N/A

Median expressionⁱ : 0.01

Median follow up timeⁱ : 0.98

P scoreⁱ 0.38

3-year survival highⁱ 13%

3-year survival lowⁱ 8%

TCGA RNA samplesⁱ

Average pTPM

0.0

Number of samples

141

Samples

Sample	Description	pTPM
TCGA-32-2634-01A	82 years, male, white, stage:'--, alive, 693 days	0.9
TCGA-08-0386-01A	74 years, male, white, stage:'--, dead, 548 days	0.8
TCGA-06-1804-01A	81 years, female, white, stage:'--, dead, 414 days	0.7
TCGA-06-2567-01A	65 years, male, white, stage:'--, dead, 133 days	0.4
TCGA-15-1444-01A	21 years, male, white, stage:'--, dead, 1537 days	0.3
TCGA-28-2509-01A	77 years, female, white, stage:'--, alive, 145 days	0.2
TCGA-14-1825-01A	70 years, male, white, stage:'--, dead, 232 days	0.1
TCGA-19-2619-01A	55 years, female, black or african american, stage:'--, alive, 294 days	0.1
TCGA-06-5416-01A	23 years, female, white, stage:'--, alive, 204 days	0.1
TCGA-27-1832-01A	59 years, female, white, stage:'--, dead, 300 days	0.1
TCGA-28-5215-01A	62 years, female, white, stage:'--, dead, 335 days	0.1
TCGA-26-5134-01A	74 years, male, white, stage:'--, alive, 167 days	0.1
TCGA-06-0743-01A	69 years, male, white, stage:'--, dead, 803 days	0.1
TCGA-06-2562-01A	81 years, male, white, stage:'--, dead, 382 days	0.1
TCGA-28-5220-01A	67 years, male, white, stage:'--, dead, 388 days	0.1
TCGA-06-0238-01A	46 years, male, white, stage:'--, dead, 405 days	0.1
TCGA-32-1970-01A	59 years, male, white, stage:'--, dead, 468 days	0.1
TCGA-12-0616-01A	36 years, female, white, stage:'--, dead, 448 days	0.1
TCGA-28-1753-01A	53 years, male, white, stage:'--, alive, 37 days	0.0
TCGA-32-2615-01A	62 years, male, white, stage:'--, dead, 485 days	0.0
TCGA-32-2616-01A	48 years, female, white, stage:'--, dead, 224 days	0.0
TCGA-12-5295-01A	60 years, female, white, stage:'--, dead, 454 days	0.0
TCGA-14-0871-01A	74 years, female, white, stage:'--, dead, 880 days	0.0
TCGA-41-2571-01A	89 years, male, white, stage:'--, dead, 26 days	0.0
TCGA-06-0645-01A	55 years, female, white, stage:'--, dead, 175 days	0.0
TCGA-19-2620-01A	70 years, male, white, stage:'--, dead, 148 days	0.0
TCGA-06-0158-01A	73 years, male, white, stage:'--, dead, 329 days	0.0
TCGA-06-0157-01A	63 years, female, white, stage:'--, dead, 97 days	0.0
TCGA-32-2632-01A	80 years, male, white, stage:'--, dead, 269 days	0.0
TCGA-06-0132-01A	49 years, male, white, stage:'--, dead, 771 days	0.0
TCGA-19-2629-01A	60 years, male, white, stage:'--, dead, 737 days	0.0
TCGA-06-5412-01A	78 years, female, white, stage:'--, dead, 138 days	0.0
TCGA-28-5216-01A	52 years, male, white, stage:'--, alive, 415 days	0.0
TCGA-06-0878-01A	74 years, male, white, stage:'--, alive, 218 days	0.0
TCGA-28-2514-01A	45 years, male, asian, stage:'--, alive, 160 days	0.0
TCGA-06-5858-01A	45 years, female, white, stage:'--, alive, 187 days	0.0
TCGA-26-5132-01A	74 years, male, white, stage:'--, alive, 286 days	0.0
TCGA-19-1390-01A	63 years, female, white, stage:'--, dead, 772 days	0.0
TCGA-06-0686-01A	53 years, male, white, stage:'--, dead, 432 days	0.0
TCGA-06-0219-01A	67 years, male, white, stage:'--, dead, 22 days	0.0
TCGA-12-0618-01A	49 years, male, white, stage:'--, dead, 395 days	0.0
TCGA-26-1442-01A	43 years, male, white, stage:'--, alive, 953 days	0.0
TCGA-06-0744-01A	66 years, male, white, stage:'--, dead, 1426 days	0.0
TCGA-76-4927-01A	58 years, male, white, stage:'--, dead, 535 days	0.0
TCGA-06-0184-01A	63 years, male, white, stage:'--, dead, 2126 days	0.0
TCGA-41-4097-01A	63 years, female, white, stage:'--, dead, 6 days	0.0
TCGA-14-1034-01A	60 years, female, stage:'--, dead, 485 days	0.0
TCGA-02-0047-01A	78 years, male, white, stage:'--, dead, 448 days	0.0
TCGA-41-3915-01A	48 years, male, white, stage:'--, dead, 360 days	0.0
TCGA-27-1834-01A	56 years, male, white, stage:'--, dead, 1233 days	0.0
TCGA-16-0846-01A	85 years, male, white, stage:'--, dead, 119 days	0.0
TCGA-06-0646-01A	60 years, male, white, stage:'--, dead, 175 days	0.0
TCGA-02-2485-01A	53 years, male, black or african american, stage:'--, alive, 470 days	0.0
TCGA-06-0174-01A	54 years, male, white, stage:'--, dead, 98 days	0.0
TCGA-06-0129-01A	30 years, male, asian, stage:'--, dead, 1024 days	0.0
TCGA-41-2572-01A	67 years, male, white, stage:'--, dead, 406 days	0.0
TCGA-28-2513-01A	69 years, female, white, stage:'--, alive, 222 days	0.0
TCGA-06-0156-01A	57 years, male, white, stage:'--, dead, 178 days	0.0
TCGA-15-0742-01A	65 years, male, white, stage:'--, dead, 419 days	0.0
TCGA-02-2486-01A	64 years, male, white, stage:'--, dead, 618 days	0.0
TCGA-06-0138-01A	43 years, male, white, stage:'--, dead, 737 days	0.0
TCGA-06-2557-01A	76 years, male, black or african american, stage:'--, dead, 33 days	0.0
TCGA-28-5208-01A	52 years, male, white, stage:'--, dead, 544 days	0.0
TCGA-12-0619-01A	60 years, male, white, stage:'--, dead, 1062 days	0.0
TCGA-32-1980-01A	72 years, male, white, stage:'--, dead, 36 days	0.0
TCGA-06-0644-01A	71 years, male, black or african american, stage:'--, dead, 384 days	0.0
TCGA-06-0750-01A	43 years, male, white, stage:'--, dead, 28 days	0.0
TCGA-76-4925-01A	76 years, male, white, stage:'--, dead, 146 days	0.0
TCGA-06-0210-01A	72 years, female, white, stage:'--, dead, 225 days	0.0
TCGA-14-1829-01A	57 years, male, black or african american, stage:'--, alive, 218 days	0.0
TCGA-06-5410-01A	72 years, female, white, stage:'--, dead, 108 days	0.0
TCGA-12-3652-01A	60 years, male, white, stage:'--, dead, 1062 days	0.0
TCGA-06-0125-01A	63 years, female, white, stage:'--, dead, 1448 days	0.0
TCGA-27-2528-01A	62 years, male, white, stage:'--, dead, 480 days	0.0
TCGA-06-2570-01A	21 years, female, white, stage:'--, alive, 958 days	0.0
TCGA-06-2563-01A	72 years, female, white, stage:'--, alive, 932 days	0.0
TCGA-76-4932-01A	50 years, female, white, stage:'--, dead, 1458 days	0.0
TCGA-06-0187-01A	69 years, male, white, stage:'--, dead, 828 days	0.0
TCGA-32-5222-01A	66 years, male, white, stage:'--, dead, 585 days	0.0
TCGA-27-2523-01A	63 years, male, white, stage:'--, dead, 489 days	0.0
TCGA-32-2638-01A	67 years, male, white, stage:'--, dead, 766 days	0.0
TCGA-27-2519-01A	48 years, male, white, stage:'--, dead, 550 days	0.0
TCGA-27-1831-01A	66 years, male, white, stage:'--, dead, 505 days	0.0
TCGA-06-2565-01A	59 years, male, asian, stage:'--, dead, 506 days	0.0
TCGA-27-2521-01A	34 years, male, white, stage:'--, dead, 510 days	0.0
TCGA-14-2554-01A	52 years, female, white, stage:'--, dead, 532 days	0.0
TCGA-02-2483-01A	43 years, male, asian, stage:'--, alive, 466 days	0.0
TCGA-06-2561-01A	53 years, female, white, stage:'--, dead, 537 days	0.0
TCGA-27-1835-01A	53 years, female, white, stage:'--, dead, 648 days	0.0
TCGA-14-1823-01A	58 years, female, white, stage:'--, dead, 543 days	0.0
TCGA-06-0882-01A	30 years, male, white, stage:'--, dead, 632 days	0.0
TCGA-32-4213-01A	47 years, female, white, stage:'--, alive, 604 days	0.0
TCGA-06-0168-01A	59 years, female, white, stage:'--, dead, 598 days	0.0
TCGA-19-2624-01A	51 years, male, white, stage:'--, dead, 5 days	0.0
TCGA-06-5408-01A	54 years, female, white, stage:'--, dead, 357 days	0.0
TCGA-41-5651-01A	59 years, female, black or african american, stage:'--, dead, 460 days	0.0
TCGA-06-5856-01A	58 years, male, white, stage:'--, dead, 114 days	0.0
TCGA-14-0817-01A	69 years, female, white, stage:'--, dead, 164 days	0.0
TCGA-28-5218-01A	63 years, male, white, stage:'--, dead, 157 days	0.0
TCGA-06-5417-01A	45 years, female, white, stage:'--, alive, 155 days	0.0
TCGA-27-1830-01A	57 years, male, white, stage:'--, dead, 154 days	0.0
TCGA-06-2559-01A	83 years, male, white, stage:'--, dead, 150 days	0.0
TCGA-32-1982-01A	76 years, female, white, stage:'--, dead, 142 days	0.0
TCGA-06-5859-01A	63 years, male, white, stage:'--, alive, 139 days	0.0
TCGA-19-2625-01A	76 years, female, white, stage:'--, dead, 124 days	0.0
TCGA-76-4929-01A	76 years, female, white, stage:'--, dead, 111 days	0.0
TCGA-19-4065-01A	36 years, male, white, stage:'--, alive, 214 days	0.0
TCGA-12-5299-01A	56 years, female, white, stage:'--, dead, 98 days	0.0
TCGA-27-2526-01A	79 years, female, white, stage:'--, dead, 87 days	0.0
TCGA-06-5418-01A	75 years, female, white, stage:'--, dead, 83 days	0.0
TCGA-06-0749-01A	50 years, male, black or african american, stage:'--, dead, 82 days	0.0
TCGA-06-0747-01A	53 years, male, white, stage:'--, dead, 82 days	0.0
TCGA-02-0055-01A	62 years, female, white, stage:'--, dead, 76 days	0.0
TCGA-14-0787-01A	69 years, male, asian, stage:'--, dead, 68 days	0.0
TCGA-26-5139-01A	65 years, female, white, stage:'--, alive, 48 days	0.0
TCGA-06-2569-01A	24 years, female, black or african american, stage:'--, alive, 13 days	0.0
TCGA-06-2564-01A	50 years, male, white, stage:'--, alive, 181 days	0.0
TCGA-27-2524-01A	56 years, male, white, stage:'--, dead, 231 days	0.0
TCGA-19-5960-01A	56 years, male, white, stage:'--, dead, 455 days	0.0
TCGA-28-5207-01A	71 years, male, white, stage:'--, dead, 343 days	0.0
TCGA-28-5204-01A	72 years, male, white, stage:'--, dead, 454 days	0.0
TCGA-26-5133-01A	59 years, male, white, stage:'--, alive, 452 days	0.0
TCGA-28-5209-01A	66 years, female, white, stage:'--, alive, 442 days	0.0
TCGA-12-3653-01A	34 years, female, white, stage:'--, dead, 442 days	0.0
TCGA-27-1837-01A	36 years, male, white, stage:'--, dead, 427 days	0.0
TCGA-06-0130-01A	54 years, male, white, stage:'--, dead, 394 days	0.0
TCGA-06-2558-01A	75 years, female, white, stage:'--, dead, 380 days	0.0
TCGA-06-0139-01A	40 years, male, white, stage:'--, dead, 362 days	0.0
TCGA-06-0211-01A	47 years, male, white, stage:'--, dead, 360 days	0.0
TCGA-14-0789-01A	54 years, male, white, stage:'--, dead, 342 days	0.0
TCGA-06-0745-01A	59 years, male, white, stage:'--, dead, 239 days	0.0
TCGA-12-3650-01A	46 years, male, white, stage:'--, dead, 333 days	0.0
TCGA-12-0821-01A	62 years, male, white, stage:'--, dead, 323 days	0.0
TCGA-06-0190-01A	62 years, male, white, stage:'--, dead, 317 days	0.0
TCGA-06-0141-01A	62 years, male, white, stage:'--, dead, 313 days	0.0
TCGA-76-4931-01A	70 years, female, white, stage:'--, dead, 279 days	0.0
TCGA-06-5414-01A	61 years, male, white, stage:'--, alive, 273 days	0.0
TCGA-26-5135-01A	72 years, female, white, stage:'--, dead, 270 days	0.0
TCGA-06-5413-01A	67 years, male, white, stage:'--, alive, 268 days	0.0
TCGA-06-5411-01A	51 years, male, white, stage:'--, dead, 254 days	0.0
TCGA-06-0178-01A	38 years, male, white, stage:'--, dead, 2681 days	0.0
Show allShow less

GLIOBLASTOMA MULTIFORME (VALIDATION) - Interactive survival scatter plotⁱ

The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.

The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".

Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.

Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.

& Survival analysisⁱ

NPY4R is not prognostic in Glioblastoma Multiforme (validation)

Stage:

Survival analysis

Current cut offⁱ :

Best expression cut offⁱ : N/A

Median expressionⁱ : 0.12

Median follow up timeⁱ : 0.99

P scoreⁱ 0.52

3-year survival highⁱ 29%

3-year survival lowⁱ 27%

TCGA RNA samplesⁱ

Average pTPM

0.3

Number of samples

58

Samples

Sample	Description	pTPM
AK185	N, NA, stage:NA, alive, 330 days	4.6
AK205	N, NA, stage:NA, dead, 120 days	4.1
AK043	N, NA, stage:NA, alive, 660 days	2.7
AK006	N, NA, stage:NA, dead, 360 days	1.3
AK030	N, NA, stage:NA, dead, 120 days	0.7
AK216	N, NA, stage:NA, dead, 360 days	0.6
AK051	N, NA, stage:NA, dead, 360 days	0.6
AK226	N, NA, stage:NA, dead, 360 days	0.6
AK165	N, NA, stage:NA, alive, 360 days	0.5
AK167	N, NA, stage:NA, dead, 180 days	0.5
AK213	N, NA, stage:NA, alive, 2010 days	0.4
AK227	N, NA, stage:NA, alive, 300 days	0.4
AK003	N, NA, stage:NA, dead, 600 days	0.4
AK149	N, NA, stage:NA, dead, 420 days	0.4
AK158	N, NA, stage:NA, dead, 360 days	0.3
AK015	N, NA, stage:NA, alive, 720 days	0.3
AK236	N, NA, stage:NA, dead, 360 days	0.3
AK103	N, NA, stage:NA, alive, 1320 days	0.3
AK055	N, NA, stage:NA, dead, 240 days	0.3
AK195	N, NA, stage:NA, dead, 390 days	0.3
AK139	N, NA, stage:NA, dead, 270 days	0.3
AK049	N, NA, stage:NA, dead, 180 days	0.2
AK153	N, NA, stage:NA, dead, 240 days	0.2
AK102	N, NA, stage:NA, alive, 1740 days	0.2
AK173	N, NA, stage:NA, dead, 180 days	0.2
AK085	N, NA, stage:NA, alive, 660 days	0.2
AK066	N, NA, stage:NA, alive, 960 days	0.2
AK134	N, NA, stage:NA, dead, 360 days	0.1
AK098	N, NA, stage:NA, dead, 660 days	0.1
AK183	N, NA, stage:NA, alive, 360 days	0.1
AK231	N, NA, stage:NA, dead, 240 days	0.1
AK156	N, NA, stage:NA, dead, 330 days	0.1
AK088	N, NA, stage:NA, dead, 360 days	0.1
AK053	N, NA, stage:NA, dead, 300 days	0.1
AK124	N, NA, stage:NA, alive, 1920 days	0.1
AK100	N, NA, stage:NA, alive, 960 days	0.1
AK188	N, NA, stage:NA, alive, 420 days	0.1
AK199	N, NA, stage:NA, alive, 1860 days	0.1
AK071	N, NA, stage:NA, dead, 540 days	0.1
AK041	N, NA, stage:NA, alive, 810 days	0.1
AK089	N, NA, stage:NA, dead, 330 days	0.1
AK218	N, NA, stage:NA, dead, 180 days	0.1
AK133	N, NA, stage:NA, dead, 360 days	0.1
AK091	N, NA, stage:NA, dead, 210 days	0.1
AK117	N, NA, stage:NA, dead, 210 days	0.1
AK142	N, NA, stage:NA, alive, 90 days	0.0
AK005	N, NA, stage:NA, dead, 240 days	0.0
AK035	N, NA, stage:NA, dead, 210 days	0.0
AK002	N, NA, stage:NA, dead, 570 days	0.0
AK079	N, NA, stage:NA, dead, 210 days	0.0
AK081	N, NA, stage:NA, dead, 180 days	0.0
AK068	N, NA, stage:NA, alive, 360 days	0.0
AK076	N, NA, stage:NA, alive, 660 days	0.0
AK123	N, NA, stage:NA, dead, 180 days	0.0
AK099	N, NA, stage:NA, dead, 420 days	0.0
AK072	N, NA, stage:NA, dead, 150 days	0.0
AK178	N, NA, stage:NA, dead, 240 days	0.0
AK074	N, NA, stage:NA, alive, 300 days	0.0
Show allShow less

GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)

Number of samples

110

Samples

Sample ID	Sample type	nRPX
CPT0206330003	Tumor	N/A
CPT0186100003	Tumor	N/A
CPT0123530003	Tumor	N/A
CPT0201710003	Tumor	N/A
CPT0216920008	Tumor	N/A
CPT0218890004	Tumor	N/A
CPT0224390004	Tumor	N/A
CPT0204390003	Normal	N/A
CPT0093590003	Tumor	N/A
CPT0167750004	Tumor	N/A
CPT0204400003	Normal	N/A
CPT0079790003	Tumor	N/A
CPT0218690004	Tumor	N/A
CPT0204370003	Normal	N/A
CPT0161730003	Tumor	N/A
CPT0168720003	Tumor	N/A
CPT0206880003	Tumor	N/A
CPT0189650004	Tumor	N/A
CPT0204350003	Normal	N/A
CPT0168380003	Tumor	N/A
CPT0205890003	Tumor	N/A
CPT0217880003	Tumor	N/A
CPT0206560003	Tumor	N/A
CPT0087680003	Tumor	N/A
CPT0206000004	Tumor	N/A
CPT0218670003	Tumor	N/A
CPT0204340003	Normal	N/A
CPT0189850004	Tumor	N/A
CPT0224330003	Tumor	N/A
CPT0218330004	Tumor	N/A
CPT0167640003	Tumor	N/A
CPT0002410011	Tumor	N/A
CPT0093450003	Tumor	N/A
CPT0206110003	Tumor	N/A
CPT0217430008	Tumor	N/A
CPT0217000004	Tumor	N/A
CPT0196850003	Tumor	N/A
CPT0189250003	Tumor	N/A
CPT0189570004	Tumor	N/A
CPT0162020003	Tumor	N/A
CPT0167530003	Tumor	N/A
CPT0207030003	Tumor	N/A
CPT0127420003	Tumor	N/A
CPT0205670004	Tumor	N/A
CPT0208980003	Tumor	N/A
CPT0206780003	Tumor	N/A
CPT0182500003	Tumor	N/A
CPT0217710008	Tumor	N/A
CPT0168830003	Tumor	N/A
CPT0182550003	Tumor	N/A
CPT0189460003	Tumor	N/A
CPT0167860004	Tumor	N/A
CPT0125220003	Tumor	N/A
CPT0171580008	Tumor	N/A
CPT0087730003	Tumor	N/A
CPT0104330003	Tumor	N/A
CPT0168590003	Tumor	N/A
CPT0205450004	Tumor	N/A
CPT0219080004	Tumor	N/A
CPT0087570003	Tumor	N/A
CPT0162140003	Tumor	N/A
CPT0175060003	Tumor	N/A
CPT0205780003	Tumor	N/A
CPT0218960004	Tumor	N/A
CPT0064650003	Tumor	N/A
CPT0125570003	Tumor	N/A
CPT0190360004	Tumor	N/A
CPT0206670004	Tumor	N/A
CPT0204380003	Normal	N/A
CPT0092440003	Tumor	N/A
CPT0162100003	Tumor	N/A
CPT0221180003	Tumor	N/A
CPT0225760003	Tumor	N/A
CPT0093510003	Tumor	N/A
CPT0190240004	Tumor	N/A
CPT0228220003	Tumor	N/A
CPT0204410003	Normal	N/A
CPT0224540004	Tumor	N/A
CPT0209440003	Tumor	N/A
CPT0089150003	Tumor	N/A
CPT0204360003	Normal	N/A
CPT0168080003	Tumor	N/A
CPT0078580003	Tumor	N/A
CPT0127480003	Tumor	N/A
CPT0204420003	Normal	N/A
CPT0218830004	Tumor	N/A
CPT0225730003	Tumor	N/A
CPT0093360003	Tumor	N/A
CPT0168270003	Tumor	N/A
CPT0206450003	Tumor	N/A
CPT0207090003	Tumor	N/A
CPT0104220003	Tumor	N/A
CPT0224600003	Tumor	N/A
CPT0087950003	Tumor	N/A
CPT0204330003	Normal	N/A
CPT0199770003	Tumor	N/A
CPT0205570003	Tumor	N/A
CPT0093550003	Tumor	N/A
CPT0167970003	Tumor	N/A
CPT0182580003	Tumor	N/A
CPT0168480003	Tumor	N/A
CPT0206230003	Tumor	N/A
CPT0189750004	Tumor	N/A
CPT0217100003	Tumor	N/A
CPT0064890003	Tumor	N/A
CPT0217190003	Tumor	N/A
CPT0218770003	Tumor	N/A
CPT0125510003	Tumor	N/A
CPT0217060003	Tumor	N/A
CPT0071100003	Tumor	N/A
Show allShow less

GLIOMA - Protein expressionⁱ A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here. Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.

Antibody stainingⁱ Antibody staining in the annotated cell types in the current human tissue is reported as not detected, low, medium, or high, based on conventional immunohistochemistry profiling in selected tissues. This score is based on the combination of the staining intensity and fraction of stained cells. Each image is clickable and will lead to virtual microscopy that enables deeper exploration of all samples and also displays staining intensity scores, fraction scores and subcellular localization as well as patient and tissue information for each sample. Ascending and descending describe two types of gradient, based on difference in staining intensity between enterocytes in crypts and apical enterocytes. Ascending - the staining intensity is stronger in apical enterocytes (towards the lumen) compared to enterocytes in the crypts (gland based) Descending - the staining is weaker in apical enterocytes compared to enterocytes in crypts	Antibody HPA027863
Staining
High
Medium
Low
Not detected
Intensity
Strong
Moderate
Weak
Negative
Quantity
>75%
75%-25%
<25%
None
Location
Nuclear
Cytoplasmic/membranous
Cytoplasmic/membranous,nuclear
None
Glioma, malignant, High grade
Glioma, malignant, Low grade
Glioma, malignant, High grade Glioblastoma, NOS

Contact

The Project

The Human Protein Atlas

The Human Protein Atlas project is funded
by the Knut & Alice Wallenberg Foundation.

contact@proteinatlas.org